ECO Animal Health Group PLC on Tuesday said the EU has approved a trademark for the company’s branding for the family of vaccine products Ecovaxxin.
This approval is in addition to Ecovaxxin already being registered as a vaccine in the US and UK, the Surrey-based animal health pharmaceutical company said, giving it ‘extensive protection in key markets for animal health products’.
ECO Animal Health said the trademark will protect all of its forthcoming vaccine products.
Starting in 2025, it plans to market its vaccine products in ‘multiple jurisdictions, with multiple planned launches over the next ten-year period’.
ECO Animal Health said the first two planned products to carry the trademark will be its poultry mycoplasma vaccines. This specifically includes Ecovaxxin MS and Ecovaxxin MG, which treat bacterial diseases in poultry.
The trademark approval supports its strategy of accelerating growth through the company’s research and development pipeline, ECO Animal Health said, with the addition of new vaccines expected to ‘significantly support sales and profit growth’ over the next ten years.
‘This trademark approval, complemented by registrations in the US and the UK, provides broad protection for the Ecovaxxin family, fortifying our commitment to advancing growth through innovative vaccine products and supporting our strategic focus on [research & development]-driven expansion at ECO Animal Health,’ said Chief Executive Officer David Hallas.
Shares in ECO Animal Health were down 1.8% to 106.50 pence each in London on Tuesday morning.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
